Low serum level of hepatitis B core‐related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy
Akihiro Matsumoto(Shinshu University), Kendo Kiyosawa(Aizawa Hospital), Kazuaki Chayama(RIKEN Center for Integrative Medical Sciences), Hiroshi Yatsuhashi(Nagasaki Medical Center), Shigeru Nakaoka(Fujirebio (Japan)), Fumitaka Suzuki(Toranomon Hospital), Hiroshi Yotsuyanagi(The University of Tokyo), Sumio Kawata(Yamagata University), Mariko Kobayashi(Toranomon Hospital), Eiji Tanaka(Shinshu University), Hiromitsu Kumada(Toranomon Hospital), Noboru Maki(Advanced Life Science Institute), Shiro Iino(University of Fukui), Shinya Nagaoka(Nagasaki Medical Center), Takeshi Okanoue(University Hospitals Birmingham NHS Foundation Trust), Masahito Minami(Kyoto Prefectural University of Medicine), Michio Imamura(Hiroshima University)
Cited by 83
Related Papers
Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
|New England Journal of Medicine|2008|1.3k
Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus
|Hepatology|1990|1.2k
Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases
|Nature Genetics|2020|591
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
|European Journal of Cancer|2011|573